Search PubMed⌕ Search

Biomedical subjects

D Bishop

Publications and source records attributed to D Bishop.

At least 109 records · Page 6Linked to original sources
PubMed1973

English translations of biomedical journal literature: availability and control.

An overview is presented of the availability and control over the past two decades of English translations of biomedical journal literature. Note is made of the various types of translation formats and their sequence of indexes. Special attention is given to the Russian-language literature, the role of the National Library of Medicine, the publication of cover-to-cover journal translations, and the priorities of languages needing translation. Present developments and future prospects are also considered, with a caveat concerning critical reviews citing untranslated materials.

Biology↗
PubMed1971

Planning the new medical school library in relation to local and regional information resources.

The first relationship of a new medical school library with local and regional medical libraries is one of dependence. This must change, as the new library grows, to a continuing state of interdependence. To accomplish this, the new library must thoughtfully design its collections and services, and must prepare for an extramural as well as an intramural clientele. Relationships with Regional Medical Library services and with Regional Medical Programs must be carefully planned. So too must be the adoption of EDP and related procedures where future compatability is important. Any new medical school library must have strength, but must never forget the need for true cooperation to give it viability.

Health Facility Planning↗
PubMed1970

Comparative carcinogenicity for mouse-skin of smoke condensates prepared from cigarettes made from the same tobacco cured by two processes.

Bright tobacco grown in Mexico was either flue-cured and redried (FC) or air-cured and bulk-fermented (AC). Both FC and AC were made into cigarettes standardized for draw resistance. FC and AC cigarettes were smoked under similar conditions in a smoking machine (one 2-second 25 ml. puff per minute down to a 20 mm. butt length). Condensates were kept at 0-4° C. until applied to the skin of mice.Three groups of 400 female Swiss mice were treated as follows: Group 1- thrice weekly application of 60 mg. FC in 0.25 ml. acetone to the clipped dorsal skin: Group 2- similar treatment with AC; Group 3-thrice weekly application of 0.25 ml. acetone only.Chemical analysis of the 2 tobaccos and 2 condensates revealed only small differences in composition and it is noteworthy that the concentration of reducing sugars was almost as high as in the AC tobacco as in the FC tobacco.The risk of development of skin tumours, particularly malignant skin tumours, was higher in FC-treated mice than in AC-treated mice (p < 0.01), but the difference may have been due to the use of equal weights of condensates rather than the use of extracts from equal numbers of cigarettes, since the AC cigarettes produced more condensate. The rates of detection of pulmonary tumours also varied between groups (p < 0.01) but this does not necessarily imply that the incidence rates of pulmonary tumours varied. There was no evidence that the detection or incidence rates of any other neoplasms, including malignant lymphoma, were affected by treatment with either of the condensates.

Animals↗
PubMed1970

The mechanism of carcinogenesis by the neutral fraction of cigarette smoke condensate.

Sixteen groups, each of 50 Swiss female SPF mice, were treated thrice weekly with various combinations of 3,4-benzopyrene (BP) and/or the neutral fraction of cigarette smoke (NF) in acetone applied to the skin. Some groups received one carcinogen, some the other and some a mixture of the two. Skin tumour incidence rates were found to increase both with the dose of NF and with the dose of BP. With BP alone a threshold dose was found beyond which a very heavy incidence rate of malignant skin tumours occurred. After correction of the results for intercurrent deaths it was found that when NF and BP are applied together as a mixture they do not act independently in the production of malignant skin tumours but interact positively. This suggests that some of the components of NF act as cocarcinogens rather than as complete carcinogens. Treatment with NF appeared to increase the incidence of malignant lymphomas. The data were not suitable for deciding whether the various treatments influenced the rates of incidence of internal tumours of other types, for example, lung tumours.

Acetone↗
PubMed1969

Veterinary medicine and the medical school library.

The study of veterinary medicine is becoming increasingly important in the progress of human medicine, and as a consequence the literature of veterinary medicine is assuming increased importance in the libraries of schools of human medicine. In the past decade programs in comparative medicine have been initiated in many centers, reestablishing the linkage between veterinary and human medicine. Since 1966 the National Library of Medicine has assumed extra responsibilities in the collection and control of veterinary medical literature. increased indexing has thus far been the major result, with a resultant increase in the need to consult veterinary journals. Advances in the veterinary curriculum and continued veterinary education have also increased demand for veterinary publications. Such demand must be foreseen and met by medical school libraries if they are to fulfill their obligations to the scholarly medical community.

Education, Medical↗
PubMedDate not supplied

Clinical outcomes in statin treatment trials: a meta-analysis.

OBJECTIVE: To determine the risk of cardiovascular events and death in patients receiving statin treatment for cholesterol regulation. METHODS: Systematic review and meta-analysis of all randomized controlled trials that were published as of April 15, 1997. Primary or secondary prevention trials or regression trials were eligible. MAIN OUTCOME MEASURES: All-cause mortality, fatal myocardial infarction (MI) or stroke, nonfatal MI or stroke, angina, and withdrawal from the studies. Both random- and fixed-effects models were run for the outcomes of interests, and results are expressed as odds ratios (ORs). Sensitivity analyses tested the impact of the study type and duration, statin treatment type, and control arm event rates. Intent-to-treat denominators were used whenever they were available, and the number needed to treat was calculated when appropriate. RESULTS: Seventeen studies (21 303 patients) were included (2 secondary prevention studies, 5 mixed primary-secondary prevention population studies, and 10 regression trials). Treatment groups included lovastatin (t = 5), pravastatin (t = 10), and simvastatin (t = 3). For all-cause mortality, the OR was 0.76 (95% confidence interval [CI], 0.67-0.86) in favor of receiving statin treatment; for fatal MI, the OR was 0.61 (95% CI, 0.48-0.78); for nonfatal MI, the OR was 0.69 (0.54-0.88); for fatal stroke, the OR was 0.77 (95% CI, 0.57-1.04); for nonfatal stroke, the OR was 0.69 (95% CI, 0.54-0.88); and for angina, the OR was 0.70 (95% CI, 0.65-0.76). CONCLUSIONS: Patients who received statin treatment demonstrated a 20% to 30% reduction in death and major cardiovascular events compared with patients who received placebo. This advantage was generally present across study types and statin treatment types and for patients with less severe dyslipidemias. The benefit in clinical outcomes was noticeable as early as 1 year.

Anticholesteremic Agents↗